Clinical Trials Logo

Buerger Disease clinical trials

View clinical trials related to Buerger Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05698979 Not yet recruiting - Raynaud Syndrome Clinical Trials

Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease

BETOX
Start date: August 30, 2023
Phase: Phase 3
Study type: Interventional

The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.

NCT ID: NCT02501018 Completed - Clinical trials for Critical Limb Ischemia

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)

Start date: November 1, 2017
Phase: Phase 2
Study type: Interventional

A prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single arm sub-study to assess the safety and potential efficacy of CLBS12 in patients with CLI due to Buerger's Disease (BD).

NCT ID: NCT00145262 Recruiting - Clinical trials for Arteriosclerosis Obliterans

TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation

Start date: August 2003
Phase: Phase 2
Study type: Observational

Clinical studies have established that implantation of bone marrow mononuclear cells (BM-MNCs) or peripheral blood mononuclear cells (PB-MNCs) into ischaemic limbs increases collateral vessel formation. We, the investigators at Nagoya University, further investigated the efficacy and safety of autologous implantation of BM-MNCs or PB-MNCs in patients with severe ischaemic limbs who have no other alternative therapeutic options. We also examined a potential limiting factor which reduced the efficacy of therapeutic angiogenesis using cell transplantation (TACT).